CN105125824A - Traditional Chinese medicine preparation for treating chronic obstructive pulmonary disease - Google Patents
Traditional Chinese medicine preparation for treating chronic obstructive pulmonary disease Download PDFInfo
- Publication number
- CN105125824A CN105125824A CN201510507282.9A CN201510507282A CN105125824A CN 105125824 A CN105125824 A CN 105125824A CN 201510507282 A CN201510507282 A CN 201510507282A CN 105125824 A CN105125824 A CN 105125824A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- parts
- medicine preparation
- chronic obstructive
- obstructive pulmonary
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the technical field of traditional Chinese medicine preparations and particularly relates to a traditional Chinese medicine preparation for treating the chronic obstructive pulmonary disease. The traditional Chinese medicine preparation for treating the chronic obstructive pulmonary disease is characterized by being composed of the following Chinese herbal medicinal ingredients in parts by weight: 5-15 parts of salvia miltiorrhiza, 5-20 parts of astragalus membranaceus, 5-15 parts of ligusticum wallichii, 5-15 parts of allium macrostemon, 5-15 parts of ephedra, 5-15 parts of gecko, 5-15 parts of epimedium herb and 1-2 parts of lactose. The traditional Chinese medicine preparation has the advantages of synergistic effect, high safety and low dependence and has an excellent effect on treating the chronic obstructive pulmonary disease; and a preparation process for the traditional Chinese medicine preparation is simple and industrial production is facilitated.
Description
Technical field
The invention belongs to technical field of traditional Chinese medicine pharmacy, what be specifically related to is a kind of Chinese medicine preparation for the treatment of chronic obstructive pulmonary disease.
Background technology
Chronic obstructive pulmonary disease is a kind of chronic bronchitis and (or) emphysema with airflow obstruction feature, the common chronic disease of pulmonary heart disease and respiratory failure can be further development of, react relevant with the abnormal inflammatory of harmful gas and deleterious particle, disability rate and case fatality rate are very high, and more than the 40 years old sickness rate in the whole world is up to 9-10%.
The definite cause of disease of chronic obstructive pulmonary disease it be unclear that, and it is generally acknowledged, with chronic bronchitis and obstructive emphysema, the morbidity that relevant factor all may participate in chronic obstructive pulmonary disease occurs.The risk factor had been found that roughly can be divided into exopathogenic factor (i.e. environmental factors) and endogenous cause of ill (i.e. individual susceptible factor) two classes.Exopathogenic factor comprises the lower crowd of smoking, the suction of dust and chemical substance, air pollution, respiratory tract infection and socioeconomic status (may with indoor and outdoors air pollution, room is crowded, nutrition is poor and other are relevant with the lower factor be associated of socioeconomic status).Endogenous cause of ill comprise inherited genetic factors, airway reactivity increased perosn, period of pregnancy, neonatal period, infancy stage or childhood period cause lung development or dysgonic individuality by a variety of causes.
Existing Drug therapy can reduce or eliminate patients symptomatic, improves Activity Endurance, reduces acute episode frequency and the order of severity and improve health status.Inhalation in Treating is first-selected, must educate the proper use of various inhaler of patient, to object and the effect of explain's treatment, contributes to patient and adheres to treatment.
At present, mostly Western medicine is adopted to the treatment of chronic obstructive pulmonary disease, though and western medicine result is good, long-term taking has drug resistance and dependency, and can bring larger side effect to human body.
Summary of the invention
The present invention is directed to above existing issue and provide the Chinese medicine preparation for the treatment of chronic obstructive pulmonary disease, this Chinese medicine preparation develops with natural Chinese medicines composition, evident in efficacy and have no side effect.The present invention selects Radix Salviae Miltiorrhizae, the Radix Astragali, Rhizoma Chuanxiong, Bulbus Allii Macrostemonis, Herba Ephedrae, Gecko, Herba Epimedii and lactose to combine, and is made by these drug regimens each efficacy of drugs produce synergism, thus has effect for the treatment of chronic obstructive pulmonary disease.
Technical scheme provided by the invention is:
Treat a Chinese medicine preparation for chronic obstructive pulmonary disease, be made up of following Chinese medicine ingredients by weight: Radix Salviae Miltiorrhizae 5-15 part, Radix Astragali 5-20 part, Rhizoma Chuanxiong 5-15 part, Bulbus Allii Macrostemonis 5-15 part, Herba Ephedrae 5-15 part, Gecko 5-15 part, Herba Epimedii 5-15 part and lactose 1-2 part.
As preferably, the Chinese medicine preparation of described treatment chronic obstructive pulmonary disease, is made up of following Chinese medicine ingredients by weight: Radix Salviae Miltiorrhizae 10 parts, the Radix Astragali 15 parts, Rhizoma Chuanxiong 10 parts, Bulbus Allii Macrostemonis 12 parts, 10 parts, Herba Ephedrae, Gecko 10 parts, Herba Epimedii 10 parts and lactose 1.5 parts.
In addition, present invention also offers the preparation method of described Chinese medicine preparation, it is characterized in that, step is as follows:
(1) taking above seven flavor medicine material by weight ratio, is first 8 times amount 70% ethanol by adding quality in Radix Salviae Miltiorrhizae, the Radix Astragali, reflux, extract, 2 times, each 2h;
(2) extracting solution filters, merging filtrate, and decompression recycling ethanol is also concentrated into the thick paste that relative density is 1.27-1.30 (65 DEG C), and decompression belt drying, pulverizes, for subsequent use;
(3) medicinal residues obtained after extracting in step (2) are mixed with Rhizoma Chuanxiong, Herba Epimedii, Gecko, Herba Ephedrae, Bulbus Allii Macrostemonis, add the water boiling and extraction 2 times that quality is 8 times amount, each 2h;
(4) extracting solution filters, and merging filtrate, is evaporated to the thick paste that relative density is 1.23-1.25 (65 DEG C);
(5) reduce pressure the thick paste that step (5) obtains belt drying respectively, pulverizes, for subsequent use;
(6) above-mentioned extract powder is added appropriate lactose, mixing, dry granulation, granulate, packaging, obtains described Chinese medicine preparation.
The pharmacological action of the Chinese medicine ingredients selected by Chinese medicine preparation of the present invention is as follows:
Radix Salviae Miltiorrhizae is the dry root welding technology of labiate Radix Salviae Miltiorrhizae (SalviamiltiorrhizaBge.).Spring, Qiu Erji excavate, removing silt, dry.Whole nation most area has distribution.Have blood circulation promoting and blood stasis dispelling, inducing menstruation to relieve menalgia, clear away heart-fire relieving restlessness, effect of removing heat from blood eliminating carbuncle.For obstruction of qi in the chest and cardialgia, gastral cavity abdomen hypochondriac pain, abdominal mass abdominal mass is gathered, pyretic arthralgia pain, dysphoria and insomnia, menoxenia, and dysmenorrhea amenorrhea, skin infection swells and ache.
The Radix Astragali, has another name called continuous stilbene.Perennial herb, high 50-100 centimetre.Originate in the ground such as the Inner Mongol, Shanxi, Gansu, Heilungkiang.The history of medicinal existing more than 2000 year so far of the Radix Astragali, it has enhancing human body immunity function, protects the liver, diuresis, defying age, anti-stress, blood pressure lowering and antibacterial action more widely.But table excess pathogen is contained, retention of dampness due to stagnation of QI, and food stagnation is stagnated, carbuncle from the beginning of or the excess syndrome such as pyretic toxicity Shang Sheng after bursting, and hyperactivity of YANG due to deficiency of YIN person, must prohibit clothes.
Rhizoma Chuanxiong (Ligusticumchuanxionghort.) is a kind of Chinese medicinal plant, main product in Guanxian county, Sichuan, in Yunnan, Guizhou, the ground such as Guangxi, be grown on gentle climatic environment.Be usually used in blood-activating and qi-promoting, wind-expelling pain-stopping, the pungent temperature of Rhizoma Chuanxiong is fragrant dry, walks and does not keep, can go loose, and the up mountain peak that reaches is pushed up; Enter blood system again, descendingly reach the sea of blood.Blood circulation promoting and blood stasis dispelling effect is extensive, the suitable various disease of stagnation of blood stasis; Wind-expelling pain-stopping, effectiveness is excellent, can control the diseases such as wind syndrome of head headache, rheumatic arthralgia.It is gas medicine in blood that former times people calls Rhizoma Chuanxiong, the functions such as pungent loose, the resolving depression of its residence of dangerous speech, sensible, pain relieving.
Bulbus Allii Macrostemonis (AlliummacrostemonBunge.) belongs to Liliaceae, allium, another name Allium macrostemon, Bullbus Allii nipponici, bitter Bulbus Allii, little Bulbus Allii, little root vegetables, little root vegetables, large head, wild Bulbus Allii, Herba Allii prattii, wild Taipa.Except Xinjiang, Qinghai, national each provinces and regions are all produced.Be born on the hillside of height above sea level less than 1500 meters, hills, mountain valley or meadow, only a few area (Yunnan and Tibet) also has on the hillside of height above sea level 3000 meters.Also there are distribution in the Soviet Union, Korea and Japan.Bulb is done medicinal, also can do vegetable and eat, in the existing cultivation in minority area.It has activating YANG and eliminating stagnation, effect of circulation of qi promoting intestinal stasis relieving, for obstruction of qi in the chest and cardialgia, and gastral cavity abdomen feeling of fullness distending pain, heavy after dysentery.
Herba Ephedrae (EphedrasinicaStapf), another name: Ephedra sinica, magnificent Herba Ephedrae is the medical herbs that " Chinese Pharmacopoeia " includes, and medicinal source is the dry herb stem of Ephedraceae plant plait Herba Ephedrae, epheday intermedia or ephedra equisetina.Tap green herb stem autumn, dry.It is warm in nature, and acrid in the mouth, micro-hardship, have effect of diaphoresis cold expelling, depressed lung-energy dispersing, inducing diuresis to remove edema, can treat anemofrigid cold, the diseases such as edema due to wind pathogen edema, bronchial asthma of breathing with cough uncomfortable in chest.
Gecko is the dry body of Gekkonidae animal Gecko (Gekkogecko.Linnaeus).Be distributed in the ground such as Jiangxi, Fujian, Guangdong, Guangxi, Guizhou, Yunnan.There is invigorating the lung and the kidney, improving inspiration by invigorating kidney-QI Dingchuan, effect of supporing yang benefit essence.Be usually used in lung kidney deficiency, dyspnea due to deficiency tachypnea, chronic cough hemoptysis, sexual impotence, seminal emission.
Herba Epimedii (EpimediumbrevicornuMaxim.), a kind of medicinal plants, also be generic name, about there are 50 kinds, mainly be distributed in the ground such as the Jiangxi of China's Mainland, Shaanxi, Hunan, Sichuan, Zhejiang, Guangxi, Anhui, Hubei, Fujian, Gansu, Guangdong and Korea, Japan, South Africa, North of Italy to Black Sea, be grown on height above sea level 200 meters to 1, the area of 750 meters, like dark and damp area, generally be born in the thick grass of hillside, limit, ditch, sylvan life, bushes and rock seam in, at present not yet by artificial introducing and planting.Herba Epimedii is a kind of Chinese conventional Chinese medicine, and have very high medical value, nourishing YIN and invigorating YANG, tonifying YANG is kept fit.Bitter and puckery flavor, suitable insomniac uses.
Lactose (Lactose) is a kind of disaccharidase, is formed glycosidic bond and is connected in β-Isosorbide-5-Nitrae-position by a part β-D-galactose with a part alpha-D-glucose.Molecular formula C
12h
22o
11, molal weight 342.3 grams.There are two kinds of anomers: alpha-lactose and beta lactose, can transform mutually in aqueous.Alpha-lactose is easy in conjunction with a part water of crystallization.Lactose exists only in mammiferous milk at occurring in nature, and a part lactose digestion can be got a point sub-glucose and a part galactose.Galactose can promote the generation of cerebroside and mucopolysaccharide class, thus grows extremely important to infant intelligence.
Compared with prior art, the beneficial effect that the present invention has is:
(1) plurality of Chinese composition carries out reasonably combined by Chinese medicine preparation of the present invention, and the composition proportion provided makes each raw material serve good synergistic function, and it is at treatment chronic obstructive pulmonary disease invention Be very effective.
(2) Chinese medicine preparation of the present invention adopts natural Chinese medicine raw material to make, and safety is high, and the property of medicine relaxes, and has no side effect, has no adverse reaction, not easily cause drug dependence after patient takes.
(3) process of Chinese medicine preparation of the present invention is simple, is easy to suitability for industrialized production.
Detailed description of the invention
Below in conjunction with specific embodiment, elaboration detailed is further done to the present invention, but embodiments of the present invention are not limited to the scope that embodiment represents.
embodiment 1:
Take Radix Salviae Miltiorrhizae 5g, Radix Astragali 5g, Rhizoma Chuanxiong 5g, Bulbus Allii Macrostemonis 5g, Herba Ephedrae 5g, Gecko 5g, Herba Epimedii 5g and lactose 1g.
Its preparation method is: (1) takes above seven flavor medicine material by weight ratio, is first 8 times amount 70% ethanol by adding quality in Radix Salviae Miltiorrhizae, the Radix Astragali, reflux, extract, 2 times, each 2h; (2) extracting solution filters, merging filtrate, and decompression recycling ethanol is also concentrated into the thick paste that relative density is 1.27 (65 DEG C), and decompression belt drying, pulverizes, for subsequent use; (3) medicinal residues obtained after extracting in step (2) are mixed with Rhizoma Chuanxiong, Herba Epimedii, Gecko, Herba Ephedrae, Bulbus Allii Macrostemonis, add the water boiling and extraction 2 times that quality is 8 times amount, each 2h; (4) extracting solution filters, and merging filtrate, is evaporated to the thick paste that relative density is 1.23 (65 DEG C); (5) reduce pressure the thick paste that step (5) obtains belt drying respectively, pulverizes, for subsequent use; (6) above-mentioned extract powder is added appropriate lactose, mixing, dry granulation, granulate, packaging, obtains described Chinese medicine preparation.
embodiment2:
Take Radix Salviae Miltiorrhizae 15g, Radix Astragali 20g, Rhizoma Chuanxiong 15g, Bulbus Allii Macrostemonis 15g, Herba Ephedrae 15g, Gecko 15g, Herba Epimedii 15g and lactose 2g.
Its preparation method is: (1) takes above seven flavor medicine material by weight ratio, is first 8 times amount 70% ethanol by adding quality in Radix Salviae Miltiorrhizae, the Radix Astragali, reflux, extract, 2 times, each 2h; (2) extracting solution filters, merging filtrate, and decompression recycling ethanol is also concentrated into the thick paste that relative density is 1.30 (65 DEG C), and decompression belt drying, pulverizes, for subsequent use; (3) medicinal residues obtained after extracting in step (2) are mixed with Rhizoma Chuanxiong, Herba Epimedii, Gecko, Herba Ephedrae, Bulbus Allii Macrostemonis, add the water boiling and extraction 2 times that quality is 8 times amount, each 2h; (4) extracting solution filters, and merging filtrate, is evaporated to the thick paste that relative density is 1.25 (65 DEG C); (5) reduce pressure the thick paste that step (5) obtains belt drying respectively, pulverizes, for subsequent use; (6) above-mentioned extract powder is added appropriate lactose, mixing, dry granulation, granulate, packaging, obtains described Chinese medicine preparation.
embodiment3:
Take Radix Salviae Miltiorrhizae 10g, Radix Astragali 15g, Rhizoma Chuanxiong 10g, Bulbus Allii Macrostemonis 12g, Herba Ephedrae 10g, Gecko 10g, Herba Epimedii 10g and lactose 1.5g.
Its preparation method: (1) takes above seven flavor medicine material is by weight ratio first 8 times amount 70% ethanol by adding quality in Radix Salviae Miltiorrhizae, the Radix Astragali, reflux, extract, 2 times, each 2h; (2) extracting solution filters, merging filtrate, and decompression recycling ethanol is also concentrated into the thick paste that relative density is 1.28 (65 DEG C), and decompression belt drying, pulverizes, for subsequent use; (3) medicinal residues obtained after extracting in step (2) are mixed with Rhizoma Chuanxiong, Herba Epimedii, Gecko, Herba Ephedrae, Bulbus Allii Macrostemonis, add the water boiling and extraction 2 times that quality is 8 times amount, each 2h; (4) extracting solution filters, and merging filtrate, is evaporated to the thick paste that relative density is 1.24 (65 DEG C); (5) reduce pressure the thick paste that step (5) obtains belt drying respectively, pulverizes, for subsequent use; (6) above-mentioned extract powder is added appropriate lactose, mixing, dry granulation, granulate, packaging, obtains described Chinese medicine preparation.
embodiment4: Chinese medicine preparation of the present invention is to the observation of curative effect of chronic obstructive pulmonary disease animal model
It is chronic obstructive pulmonary disease insufficiency of QI of the lung and kidney, syndrome of phlegm and blood stasis obstructing lung that this Chinese medicine preparation adapts to disease, and main manifestations is that cough is coughed up phlegm, and dyspnea with rapid and short breath is breathed hard, aversion to cold and cold limbs, edema of lower limbs, purplish tongue, thin white fur of tongue, thready and hesitant pulse or heavy thin.
4.1 material
4.1.1 by reagent
Chinese medicine preparation of the present invention.
4.1.2 medicine is contrasted
Aminophylline tablets, 0.1g/ sheet, lot number 140605, is produced by Hayao Group Sanjing Pharmaceutical 4th Factory Co., Ltd..
4.1.3 animal
SD rat 50, male, body weight 180-200g, cleaning grade, the western general and-Bi Kai laboratory animal company limited in Shanghai, the quality certification number: (Shanghai) 2008-0016.
4.1.4 instrument
Red flag board medicated cigarette, tar content 11mg, nicotine content in smoke 0.7mg;
PowerLab16/35 Biological Signal Collecting System, ADInstruments Australia produces.
4.2 experimental technique
60 SD rats are divided into 6 groups at random, are respectively Normal group, model control group, aminophylline group 0.054g/kg, the high, medium and low dosage group of the white flat lung of stilbene, 1.48,0.74,0.37g crude drug/kg.LPS is mixed with 1mg/ml with physiological saline solution.In the 1st, the 14th day 10% chloral hydrate 0.35g/kg intraperitoneal injection of anesthesia rat, cervical region median incision 2cm, be separated trachea, microsyringe is by trachea to lung direction instillation LPS (200 μ g/200 μ L), and rat is put into the smoked 1h/d of 5% medicated cigarette (red flag board) smog and copies COPD model by 2nd ~ 30 days (except the 14th day).Matched group: not doing any intervention is blank.The each dosage group of the white flat lung capsule of stilbene, aminophylline group rises by 10ml/kg dosage gastric infusion on the 1st day, every day 1 time, altogether 30d.After last administration 30min, ip10% chloral hydrate 0.35g/kg anesthetized rat is drawn materials.
4.3 Testing index
4.3.1 lung function
Rat 10% chloral hydrate 0.35g/kg is anaesthetized, in the row tracheotomy of cervical region center, insert the tracheal intubation being connected with three-way cock, dorsal position is placed, and measures the parameter values such as the 0. 3 second FEC (FEV0.3), forced vital capacity (FVC), maximal midexpiratary flow curve (MMF) and End--tidal PCO_2 (PEF).
4.3.2 cytokine assay MPO and SOD, MDA, TNF-a and IL-1 β
Each treated animal opens thoracic cavity rapidly after putting to death, and it is pending that liquid nitrogen put into by taking-up middle lobe of right lung.Lung tissue is weighed, and adds normal saline 1ml with 0.1g lung tissue, uses glass homogenizer homogenate, 4 DEG C of low-temperature centrifugation (3000rmin
-1), get supernatant-70 DEG C frozen, detect by test kit illustration method.
4.4 statistical method
Data with mean ± standard deviation represent (
), quantitative response statistics method adopts one factor analysis of variance method of inspection, statistic software SPSS 17.0.
4.5 experimental result
4.5.1 Chinese medicine preparation of the present invention is on the impact of chronic obstructive induced lung injury in rats pulmonary function
Model group FVC, FEV0.3, FEV0.3/FVC compared with normal group obviously decline (P<0.01), show modeling success.The high, medium and low dosage group of the white flat lung of stilbene and aminophylline group FVC, FEV0.3, FEV0.3/FVC, PEF comparatively model group have clear improvement (P<0.01, P<0.05), the results are shown in Table 1.
Table 1. Chinese medicine preparation of the present invention is on the impact of chronic obstructive pulmonary disease pulmonary function
n=10
Note: compare with normal group,
△p<0.05,
△ △p<0.01 compares with model group, * * P<0.01; * P<0.05
4.5.2 Chinese medicine preparation of the present invention is on the impact of chronic obstructive induced lung injury in rats lung tissue SOD, MDA, IL-1 β, TNF-alpha content
Result is as shown in table 2, and model group is compared with Normal group, and Content of MDA obviously rises, and SOD is active obviously declines (P<0.01).The white flat lung high dose group of stilbene, middle dosage group, low dose group and aminophylline group obviously reduce MDA content, enhance SOD active function (P<0.01, P<0.05).
Model group is compared with Normal group, and lung tissue IL-1 β, TNF-alpha content obviously raises (p<0.01).The white flat lung high dose group of stilbene, middle dosage group, low dose group and aminophylline group obviously reduce IL-1 β, TNF-alpha content (p<0.01, p<0.05), the results are shown in Table 2.
Table 2. Chinese medicine preparation of the present invention is on the impact of the rats with chronic obstructive pulmonary factor
n=10
Note: compare with normal group,
△p<0.05,
△ △p<0.01 compares with model group, * * P<0.01; * P<0.05
4.6 conclusion
Result shows, the therapeutical effect that Chinese medicine preparation of the present invention is certain to the equal tool of rat chronic obstructive pulmonary disease, its preliminary mechanism of action may with improve pulmonary function, improve anti-oxidation stress ability and lower inflammatory reaction relevant.
embodiment5: clinical efficacy is investigated
For verifying the therapeutic effect of Chinese medicine preparation of the present invention, choosing 100 routine Patients with Chronic Obstructive Pulmonary Disease and taking 500 doses of arbitrary obtained Chinese medicine preparation of employing above-described embodiment 1-3.Wherein male 45 example, women 55 example, age 18-65 year, 40 years old mean age.The instructions of taking of Chinese medicine preparation of the present invention is: daily 1 dose/people, and every agent divides takes for 2 times sooner or later, within 5 days, is a course for the treatment of.
The diagnostic criteria of this disease is:
(1) determine according to comprehensive analysis the such as the risk factors such as smoking, clinical symptoms, sign and pulmonary function test.Not exclusively reversible flow limitation is the necessary requirement of COPD diagnosis.After sucking bronchodilatation medicine, FEV1/FVC<70% can be defined as incomplete reversible airflow limitation.
(2) small number of patients there is no the symptom such as cough, expectoration, obviously tachypnea, only finds FEV1/FVC<70% when pulmonary function test, except after other diseases, also diagnosable is COPD.
The efficacy assessment standard of Chinese medicine preparation of the present invention is: through treating 5 days, men and women two groups of patients is compared;
(1) effective: symptom major part alleviates.
(2) effective: symptom takes a turn for the better to some extent.
(3) invalid: symptom, without improvement, need adjust therapeutic scheme.
The survey showed that, and choose 100 routine Patients with Chronic Obstructive Pulmonary Disease took Chinese medicine preparation of the present invention after 5 days, recovery from illness 83 example, effective 6 examples, effective 5 examples, and invalid 6 examples, total effective rate is 94%.
The aforementioned description to concrete exemplary of the present invention is to illustrate and the object of illustration.These descriptions not want the present invention to be defined as disclosed precise forms, and obviously, according to above-mentioned instruction, can much change and change.The object selected exemplary embodiment and describe is to explain certain principles of the present invention and practical application thereof, thus those skilled in the art can be realized and utilize various different exemplary of the present invention and various different selection and change.Scope of the present invention is intended to limited by claims and equivalents thereof.
Claims (3)
1. treat the Chinese medicine preparation of chronic obstructive pulmonary disease for one kind, it is characterized in that, be made up of following Chinese medicine ingredients by weight: Radix Salviae Miltiorrhizae 5-15 part, Radix Astragali 5-20 part, Rhizoma Chuanxiong 5-15 part, Bulbus Allii Macrostemonis 5-15 part, Herba Ephedrae 5-15 part, Gecko 5-15 part, Herba Epimedii 5-15 part and lactose 1-2 part.
2. Chinese medicine preparation as claimed in claim 1, is characterized in that, be made up of by weight following Chinese medicine ingredients: Radix Salviae Miltiorrhizae 10 parts, the Radix Astragali 15 parts, Rhizoma Chuanxiong 10 parts, Bulbus Allii Macrostemonis 12 parts, 10 parts, Herba Ephedrae, Gecko 10 parts, Herba Epimedii 10 parts and lactose 1.5 parts.
3. the preparation method of Chinese medicine preparation as claimed in claim 1 or 2, it is characterized in that, step is as follows:
(1) take above seven flavor medicine material by weight ratio, be first 8 times amount 70% ethanol by adding quality in Radix Salviae Miltiorrhizae, the Radix Astragali, reflux, extract, 2 times, extracts 2h at every turn;
(2) extracting solution filters, merging filtrate, and decompression recycling ethanol is also concentrated into the thick paste that relative density is 1.27-1.30 (65 DEG C), and decompression belt drying, pulverizes, for subsequent use;
(3) medicinal residues obtained after extracting in step (2) are mixed with Rhizoma Chuanxiong, Herba Epimedii, Gecko, Herba Ephedrae, Bulbus Allii Macrostemonis, add the water boiling and extraction 2 times that quality is 8 times amount, extract 2h at every turn;
(4) extracting solution filters, and merging filtrate, is evaporated to the thick paste that relative density is 1.23-1.25 (65 DEG C);
(5) reduce pressure the thick paste that step (5) obtains belt drying respectively, pulverizes, for subsequent use;
(6) above-mentioned extract powder is added appropriate lactose, mixing, dry granulation, granulate, packaging, obtains described Chinese medicine preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510507282.9A CN105125824A (en) | 2015-08-18 | 2015-08-18 | Traditional Chinese medicine preparation for treating chronic obstructive pulmonary disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510507282.9A CN105125824A (en) | 2015-08-18 | 2015-08-18 | Traditional Chinese medicine preparation for treating chronic obstructive pulmonary disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105125824A true CN105125824A (en) | 2015-12-09 |
Family
ID=54711637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510507282.9A Pending CN105125824A (en) | 2015-08-18 | 2015-08-18 | Traditional Chinese medicine preparation for treating chronic obstructive pulmonary disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105125824A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105287726A (en) * | 2015-12-10 | 2016-02-03 | 辽宁中医药大学附属医院 | Traditional Chinese medicine preparation applied to Yongquan acupoint for preventing and treating repeated attack of cough and asthma of chronic pulmonary system diseases |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101143201A (en) * | 2006-09-11 | 2008-03-19 | 上海玉安药业有限公司 | Medicine for treating chronic obstructive lung disease and its preparation method |
| CN102038841A (en) * | 2010-12-06 | 2011-05-04 | 安徽中医学院第一附属医院(安徽省中医院) | Chinese medicine capsules for treating chronic obstructive pulmonary disease (COPD) with stagnated phlegm obstructing lung and preparation method thereof |
| CN102335274A (en) * | 2010-07-28 | 2012-02-01 | 复旦大学附属华山医院 | Chinese medicinal composition for preventing and treating inflammation-related diseases |
-
2015
- 2015-08-18 CN CN201510507282.9A patent/CN105125824A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101143201A (en) * | 2006-09-11 | 2008-03-19 | 上海玉安药业有限公司 | Medicine for treating chronic obstructive lung disease and its preparation method |
| CN102335274A (en) * | 2010-07-28 | 2012-02-01 | 复旦大学附属华山医院 | Chinese medicinal composition for preventing and treating inflammation-related diseases |
| CN102038841A (en) * | 2010-12-06 | 2011-05-04 | 安徽中医学院第一附属医院(安徽省中医院) | Chinese medicine capsules for treating chronic obstructive pulmonary disease (COPD) with stagnated phlegm obstructing lung and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 余小萍: "《黄吉赓肺病临证经验集》", 31 May 2011, 上海科学技术出版社 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105287726A (en) * | 2015-12-10 | 2016-02-03 | 辽宁中医药大学附属医院 | Traditional Chinese medicine preparation applied to Yongquan acupoint for preventing and treating repeated attack of cough and asthma of chronic pulmonary system diseases |
| CN105287726B (en) * | 2015-12-10 | 2019-09-17 | 辽宁中医药大学附属医院 | Stick the Chinese materia medica preparation that Yongquan acupoint prevents and treats chronic lung pattern disease cough and asthma recurrent exerbation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105920307A (en) | Oral traditional Chinese medicine preparation for treating influenza | |
| CN101983675A (en) | Traditional Chinese medicine composition for treating asthma and preparation method thereof | |
| CN104940485A (en) | Traditional Chinese medicine composition for treating infantile asthma and preparation method thereof | |
| CN108042683A (en) | A kind of integration of drinking and medicinal herbs product of anti-haze clearing lung-heat | |
| CN104491672A (en) | Traditional Chinese medicine preparation for treating chronic tracheitis and preparation method thereof | |
| CN105381310A (en) | Traditional Chinese medicine preparation for treating phthisis and preparing method thereof | |
| CN102614269B (en) | Method for preparing traditional Tibetan medicine for treating pharyngitis | |
| CN105125824A (en) | Traditional Chinese medicine preparation for treating chronic obstructive pulmonary disease | |
| CN104324280B (en) | It is a kind of to treat Chinese medicine composition of nasopharyngeal carcinoma and preparation method thereof | |
| CN103861041B (en) | A kind of Chinese medicine composition for the treatment of acute and chronic rhinitis and preparation method thereof | |
| CN104082538B (en) | For preventing and treating the feed of swine influenza | |
| CN103768153B (en) | Traditional Chinese medicine composition for treating air sacculitis of poultry and preparation method thereof | |
| CN105194234A (en) | Traditional Chinese medicine preparation for treating chronic obstructive pulmonary diseases | |
| CN105125838A (en) | Traditional Chinese medicine composite for treating infantile asthma and preparing method thereof | |
| CN105311337A (en) | Chinese herbal compound composition for treating lung diseases and preparation method thereof | |
| CN105381044A (en) | Traditional Chinese medicine composition for preventing and controlling muscular stomach erosion symptoms of poultry | |
| CN104547859A (en) | Application of traditional Chinese medicine preparation in preparation of medicine for treating chronic tracheitis | |
| CN103566029B (en) | Pharmaceutical composition for treating respiratory diseases and preparation method and usage thereof | |
| CN105168860A (en) | Traditional Chinese medicine composite for treating infantile asthma and preparation method thereof | |
| CN105434670A (en) | Traditional Chinese medicine preparation for treating costal chondritis and preparation method thereof | |
| CN104922396A (en) | Chinese herba preparation for treating ascariasis and preparation method | |
| CN103735820B (en) | A kind ofly treat the pharmaceutical composition that pulmonary abscess and lung qi are breathed heavily | |
| CN104398636A (en) | Traditional Chinese medicine preparation for treating bronchitis and asthma and preparation method of traditional Chinese medicine preparation | |
| CN102600261B (en) | Tibetan medicine for treating pharyngitis | |
| CN103623389A (en) | Traditional Chinese medicinal composition for treating wind-cold type pediatric bronchitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20151209 |